Thursday, July 11, 2013

Update in some Hematology Malignancies

We will be in Miami for a full report on this Topic in early August, but in the meantime,
about Ibrutinib " Now, updated data show that progression-free survival in patients with treatment-naïve CLL was 96% at 15 months and in relapsed/refractory patients was 87.7% at 18 months." (McCall )
Response even in CLL Bulky disease. An temporary Upsurge in lymphocytosis  was reported but soon settles down.

*"Ponatinib is approved for use in patients with chronic myeloid leukemia (CML) and also Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (Ph+ ALL) who have relapsed or are refractory to other therapies. Many of these patients, but not all, have developed a T315I mutation, which makes the disease resistant to the standard treatment with tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec)."
(Medscape)  Watch Amylase and lipase and marrow suppression.  READ ORIGINAL ARTICLE BY Z.CHUSTECKA.

*R. NELSON REPORTED ON NEW FDA APPROVAL OF BOSUTINIB!
" Currently, there are no approved therapies available for CML patients who have failed treatment with imatinib (Gleevec, Novartis) and the second-generation products nilotinib (Tasigna, Novartis Oncology) and dasatinib (Sprycel, Bristol-Myers Squibb).
Bosutinib is an oral, once-daily, second-generation inhibitor of Abl and Src family kinases. It is a potent ATP-competitive inhibitor of the BCR-ABL oncogene, and unlike competitors, it has minimal inhibitory activity against c-KIT and PDGFR."

AT THE END YOU NEED PRACTICAL NEWS THANKS TO MEDSCAPE!

No comments: